Carbohydrate-deficient transferrin: Validity of a new alcohol biomarker in a sample of patients with diabetes and hypertension

Journal of the American Board of Family Practice

Volumn 17, Issue 4, 2004, Pages 247-255

  Fleming, Michael ^a,b   Mundt, Marlon ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BIOLOGICAL MARKER; CARBOHYDRATE DEFICIENT TRANSFERRIN; CARBOHYDRATE-DEFICIENT TRANSFERRIN; DRUG DERIVATIVE; TRANSFERRIN;

ALCOHOL ABUSE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRINKING BEHAVIOR; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; SAMPLE; ADULT; ALCOHOLISM; BLOOD; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; REPRODUCIBILITY; RISK FACTOR; ROC CURVE; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ADULT; ALCOHOLISM; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TRANSFERRIN;

EID: 16644379483     PISSN: 08938652     EISSN: 15448770     Source Type: Journal    
DOI: 10.3122/jabfm.17.4.247     Document Type: Article

References (44)

1. Wei M, Gibbons LW, Mitchell TL, Kanpert JB, Blair SN. Alcohol intake and incidence of type 2 diabetes in men. Diabetes Care 2000;23:18-22.
2. Tsumura K, Hayashi T, Suematsu C, Endo G, Fujii S, Okada K. Daily alcohol consumption and the risk of type 2 diabetes in Japanese men: The Osaka Health Survey. Diabetes Care 1999;22:1432-7.
3. Turner BC, Jenkins E, Kerr D, Sherwin RS, Cavan DA. The effect of evening alcohol consumption on next-morning glucose control in type 1 diabetes. Diabetes Care 2001;24:1888-93.
4. Kao WH, Puddey IB, Boland LL, Watson RL, Brancati FL. Alcohol consumption and the risk of type 2 diabetes mellitus: atherosclerosis risk in communities study. Am J Epidemiol 2001;154:748-57.
5. Wartenberg AA. Management of common medical problems. In: Graham AW, Schultz TK, Wilford BB, editors. Principles of addiction medicine. Chevy Chase (MD): American Society of Addiction Medicine; 1998. p. 731-9.
6. Sikkink J, Fleming M. Adverse health effects and medical complications of alcohol, nicotine and drug use. In: Fleming MF, Barry KL, editors. Addictive disorders. St. Louis: Mosby Year Book; 1992. p. 145-68.
7. Weathermon R. Alcohol and medication interactions. Alcohol Health Res World 1999;23:40-54.
8. Fleming MF, Mihic SJ, Harris RA. Ethanol. In: Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill Medical Pub; 2001. p. 429-46.
9. Godsland IF, Leyva F, Walton C, Worthington C, Stevenson JC. Association of smoking and physical activity with risk factors for coronary heart disease and diabetes in the first follow-up cohort of the Heart Disease and Diabetes Risk Indicators in a Screened Cohort study (HDDDRISC-1). J Intern Med 1998;244:33-41.
10. Dawson DA. US low-risk drinking guidelines: an examination of four alternatives. Alcohol Clin Exp Res 2000;24:1820-9.
11. Physicians' guide to helping patients with alcohol problems. Bethesda (MD): US Department of Health and Human Services, Public Health Service, National Institutes of Health. NIH publication no. 95-3769. Available at: http://www.niaaa.nih.gov/publications/physicn.htm
12. Harasymiw J, Bean P. The combined use of the early detection of alcohol consumption (EDAC) test and carbohydrate-deficient transferrin to identify heavy drinking behaviour in males. Alcohol Alcohol 2001;36:349-53.
13. Montalto NJ, Bean P. Use of contemporary biomarkers in the detection of chronic alcohol use. Med Sci Monit 2003;9:RA285-90.
14. Stowell L, Stowell A, Garrett N, Robinson G. Comparison of serum β-hexosaminidase isoenzyme β activity with serum carbohydrate-deficient transferrin and other markers of alcohol abuse. Alcohol Alcohol 1997;32:703-14.
15. Center for Medicare & Medicaid Services, (CMS), HHS. Medicare program; negotiated rulemaking: coverage and administrative policies for clinical diagnostic laboratory services. Final rule. Fed Regist 2001;66:58788-890.
16. Bird WF Jr. Detecting alcohol abuse: the value of carbohydrate-deficient transferrin. J Insur Med 1997;29:126-35.
17. Sillanaukee P, Aalto M, Seppa K. Carbohydrate deficient transferrin and conventional alcohol markers as indicators for brief intervention among heavy drinkers in primary health care. Alcohol Clin Exp Res 1998;22:892-6.
18. Tonnesen H, Carstensen M, Maina P. Is carbohydrate-deficient transferrin a useful marker of harmful alcohol intake among surgical patients?. Eur J Surg 1999;165:522-7.
19. Gomez A, Conde A, Aguiar JA, Santana JM, Jorrin A, Betancor P. Diagnostic usefulness of carbohydrate-deficient transferrin for detecting alcohol-related problems in hospitalized patients. Alcohol Alcohol 2001;36:266-70.
20. Spies CD, Kissner M, Neumann T, Blum S, Voigt D, Funk T, et al. Elevated carbohydrate-deficient transferring predicts prolonged intensive care unity stay in traumatized men. Alcohol Alcohol 1998;33:661-9.
21. Wetterling T, Kanitz RD, Renner F, Fischer D. Does CDT predict the severity of alcohol withdrawal syndrome? Alcohol Clin Exp Res 1998;22:1053-6.
22. Mundle G, Ackerman K, Munkes J, Steinle D, Mann K. Influence of age, alcohol consumption and abstinence on the sensitivity of carbohydrate deficient transferrin, gamma-glutamyltransferase and mean corpuscular volume. Alcohol Alcohol 1999;34:760-6.
23. Brathen G, Bjerve KS, Brodtkorb E, Helde G, Bovim G. Detection of alcohol abuse in neurological patients: variables of clinical relevance to the accuracy of the %CDT-TIA and CDTect methods. Alcohol Clin Exp Res 2001;25:46-53.
24. Sillanaukee P, Alho H, Strid N, et al. Effect of hormone balance on carbohydrate-deficient transferrin and gamma-glutamyltransferase in female social drinkers. Alcohol Clin Exp Res 2000;24:1505-9.
25. Whitfield JB, Zhu G, Heath AC, Powell LW, Martin NG. Effects of alcohol consumption on indices of iron stores and or iron stores on alcohol intake markers. Alcohol Clin Exp Res 2001;25:1037-45.
26. Whitfield JB, Fletcher LM, Murphy TL, et al. Smoking, obesity, and hypertension alter the doseresponse curve and test sensitivity of carbohydrate deficient transferrin as a marker of alcohol intake. Clin Chem 1998;44:2480-9.
27. Meerkerk GJ, Njoo KH, Bongers IM, Trienekens P, vanOers JAM. Comparing the diagnostic accuracy of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean cell volume in a general practice population. Alcohol Clin Exp Res 1999;23:1052-9.
28. Sillanaukee P, Strid N, Jousilahti P, et al. Association of self-reported diseases and health care use with commonly used laboratory markers for alcohol consumption. Alcohol Alcohol 2001;36:339-45.
29. Bean P. Carbohydrate-deficient transferrin in the assessment of harmful alcohol consumption: diagnostic performance and clinical significance. Addiction Biology 1999;4:151-61.
30. Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the Alcohol Timeline Followback when administered by telephone and by computer. Drug Alcohol Depend 1996;42:49-54.
31. Grant BF. Prevalence of the proposed DSM-IV alcohol use disorders: United States, 1988. Br J Addict 1992;87:309-16.
32. Anton R, Lieber C, Tabakoff B, CDTect Study Group. Carbohydrate-deficient transferrin and gamma-Glutamyltransferase for the detection and monitoring of alcohol use: results from a multisite study. Alcohol Clin Exp Res 2002;26:1215-22.
33. Fleming MF, Barry KL, Manwell LB, Johnson K, London R. Brief physician advice for problem alcohol drinkers: a randomized controlled trial in community-based primary care practices. JAMA 1997;277:1039-45.
34. Allen JP, Sillamaukee P, Anton R. Contribution of carbohydrate-deficient transferrin to gamma glutamyl transpeptidase in evaluating progress of patients in treatment for alcoholism. Alcohol Clin Exp Res 1999;23:115-20.
35. Anton R, Moak D, Latham P. Carbohydrate deficient transferrin as an indicator of drinking status during a treatment outcome study. Alcohol Clin Exp Res 1996;20:841-6.
36. Aertgeerts B, Buntinx F, Ansoms S, Fevery J. Screening properties of questionnaires and laboratory tests for the detection of alcohol abuse or dependence in a general practice population. Br J Gen Pract 2001;51:206-17.
37. Huseby N, Nillsen O, Erfurth A, Wetterling T, Kanitz R. Carbohydrate-deficient transferrin and alcohol dependency: variation in response to alcohol intake among different groups of patients. Alcohol Clin Exp Res 1997;21:201-5.
38. Stibler H, Borg S, Allgulander C. Clinical significance of abnormal heterogeneity of transferrin in relation to alcohol consumption. Acta Med Scand 1979;206:275-81.
39. Brathen G, Bjerve KS, Brodtkorb E, Bovim G. Validity of carbohydrate-deficient transferrin and other markers as diagnostic aids in the detection of alcohol related seizures. J Neurol Neurosurg Psychiatry 2000;68:342-8.
40. de Jong G, van Noort WL, Feelders RA, de Jeu-Jaspars CMH, van Eijk HG. Adaptation of transferrin protein and glycan synthesis. Clin Chim Acta 1992;212:27-45.
41. Fleming MF, Mundt MP, French MT, Manwell LB, Stauffacher EA, Barry KL. Brief physician advice for problem drinkers: long-term efficacy and benefit cost analysis. Alcohol Clin Exp Res 2002;26:36-43.
42. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2000. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention; 2002.
43. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas (TX): American Heart Association; 2001.
44. Heinemann A, Sterneck M, Kuhlencordt R, et al. Carbohydrate deficient transferrin: diagnostic efficiency among patients with end-stage liver disease before and after liver transplantation. Alcohol Clin Exp Res 1998;22:1806-12.